Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Invariant or Type 1 NKT cells (iNKT cells) are a unique population of lymphocytes that share characteristics of T cells and natural killer (NK) cells. Various studies have shown that positive costimulatory pathways such as the CD28 and CD40 pathways can influence the expansion and cytokine production by iNKT cells. However, little is understood about the regulation of iNKT cells by negative costimulatory pathways. Here, we show that in vivo activation with α-GalCer results in increased cytokine production and expansion of iNKT cells in the absence of programmed cell death ligand-1 (PD-L1, B7-H1, and CD274). To study whether PD-L1 deficiency on NKT cells would enhance antigen-specific T-cell responses, we utilized CD8(+) OT-1 OVA transgenic T cells. α-GalCer enhanced the expansion and cytokine production of OT-1 CD8(+) cells after adoptive transfer into wild-type recipients. However, this expansion was significantly enhanced when OT-1 CD8(+) T cells were adoptively transferred into PD-L1(-/-) recipients. To extend these results to a tumor model, we used the B16 melanoma system. PD-L1(-/-) mice given dendritic cells loaded with antigen and α-GalCer had a significant reduction in tumor growth and this was associated with increased trafficking of antigen-presenting cells and CD8(+) T cells to the tumors. These data demonstrate that abrogating PDL1:PD-1 interactions during the activation of iNKT cells amplifies an anti-tumor response when coupled with DC vaccination.
Research Division, Puget Sound Blood Center, Seattle, WA 98104, USA.
Kevin
K
Durgan
Mohamed
M
Ali
Paul
P
Warner
Yvette E
YE
Latchman
D019264:Adoptive Transfer; D000818:Animals; D018122:B7-1 Antigen / Q000276:immunology* / Q000378:metabolism; D060890:B7-H1 Antigen; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D002469:Cell Separation; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005699:Galactosylceramides / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology*; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D055611:Natural Killer T-Cells / Q000276:immunology* / Q000378:metabolism; D010455:Peptides / Q000276:immunology* / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology*
D018122:B7-1 Antigen; D060890:B7-H1 Antigen; D019496:Cancer Vaccines; C498919:Cd274 protein, mouse; D016207:Cytokines; D005699:Galactosylceramides; D008562:Membrane Glycoproteins; D010455:Peptides; C493154:alpha-galactosylceramide
J Immunol. 2008 Nov 15;181(10):6707-10
18981087
Nat Immunol. 2010 Mar;11(3):197-206
20139988
J Immunol. 2001 May 15;166(10):6012-8
11342617
J Exp Med. 2007 Oct 29;204(11):2641-53
17923500
J Exp Med. 2003 Jul 21;198(2):267-79
12874260
J Immunol. 2005 Sep 1;175(5):3092-3101
16116198
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691-6
15249675
Clin Cancer Res. 2009 Mar 1;15(5):1623-34
19208793
J Immunol. 2009 Jun 1;182(11):6644-7
19454657
J Exp Med. 1996 Jan 1;183(1):87-97
8551248
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103
9223321
J Exp Med. 2006 Apr 17;203(4):883-95
16606670
Cancer Immunol Immunother. 2009 May;58(5):699-708
18807035
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
20160101
J Exp Med. 2001 Oct 15;194(8):1179-86
11602646
Nat Immunol. 2002 Dec;3(12):1163-8
12415264
J Immunol. 2008 Jul 15;181(2):907-17
18606642
J Exp Med. 2008 Sep 1;205(9):2125-38
18725522
Int Immunol. 2000 Jul;12(7):987-94
10882410
J Leukoc Biol. 2004 Aug;76(2):307-13
15123775
Immunity. 2007 Jul;27(1):111-22
17629517
Mol Ther. 2006 Jan;13(1):194-202
16112911
Nat Immunol. 2002 Sep;3(9):867-74
12154358
J Clin Invest. 2007 May;117(5):1195-203
17476349
J Immunol. 2009 Mar 1;182(5):2816-26
19234176
Annu Rev Immunol. 2005;23:877-900
15771592
Cancer Res. 1999 Jul 15;59(14):3340-5
10416590
J Immunol. 2008 Apr 15;180(8):5448-56
18390727
Nat Rev Immunol. 2004 Mar;4(3):231-7
15039760
J Immunol. 1999 Nov 1;163(9):4647-50
10528160
Biochem Biophys Res Commun. 2005 Feb 4;327(1):201-7
15629449
J Exp Med. 1999 Apr 5;189(7):1121-8
10190903
J Immunol. 2009 Dec 15;183(12):7898-908
20007574
PLoS One. 2008 Jul 16;3(7):e2703
18628995
Exp Gerontol. 2002 Jan-Mar;37(2-3):213-7
11772506
J Immunol. 1999 Jul 15;163(2):699-707
10395660
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8395-400
12829795
J Exp Med. 2009 Dec 21;206(13):3015-29
20008522
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9331-6
18599457
Science. 1997 Nov 28;278(5343):1626-9
9374463
J Exp Med. 2004 Jun 21;199(12):1607-18
15197224
Annu Rev Immunol. 2003;21:483-513
12543936
Science. 1996 Mar 22;271(5256):1734-6
8596936
Cancer Immunol Immunother. 2008 Nov;57(11):1679-83
18369622